title: Management of heart failure patients in Poland.
abstract: Over the next 10 years, heart failure is likely to become a medical and sociological problem as a result of improved treatment of ischaemic heart disease and hypertension. At present, in Poland, there are only 50% of the cardiological or cardiac surgery procedures (coronarography, PTCA, CABG, surgery of congenital or acquired heart disease) performed compared to Western Europe. After being registered on the waiting list, it can take anything between 3 and 12 months before the procedure is done. Patients with heart failure have diagnostic tests such as ECG, chest X-ray, and biochemical evaluation performed regardless of the level of care. When echocardiography, exercise testing or Holter monitoring is required, it is done at specialist or reference specialist facilities with a waiting time of approximately 1-3 months. Pharmaceutical treatment of CHF is also inadequate. ACE inhibitors are prescribed in approximately 68% of patients. The average prescribed dosage is far from that recommended in guidelines. Only 18-29% of patients with HF are on beta blockers. The improvement of cardiological care standards depends mainly on the financial resources of State Health System Agencies.
authors.affiliation: II Department of Valvular heart Disease, Stefan Cardinal Wyszynski, National Institute of Cardiology, Alpejska str.42, 04-828, Warszawa, Poland. jkorewicki@ikard.waw.pl
authors.forename: J
authors.initials: J
authors.lastname: Korewicki
authors.forename: S
authors.initials: S
authors.lastname: Rywik
authors.forename: T
authors.initials: T
authors.lastname: Rywik
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002309:Cardiology; D004452:Echocardiography; D004562:Electrocardiography; D006297:Health Services Accessibility; D006333:Heart Failure / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D011044:Poland / Q000453:epidemiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors